# Kymera Therapeutics

KT-474 is an IRAK4 degrader (co-developed with Sanofi) whose structural basis for selective and potent IRAK4 degradation was published in Nature Communications, underpinning dermatology and autoimmunity indications.


Source: https://en.bioecon.ru/companies/kymera-therapeutics/
Updated: 2026-07-20

- Country: United States
- Ticker: KYMR

## Technologies

- [PROTACs (targeted protein degradation)](https://en.bioecon.ru/technology/protacs/)